BioSpace News Archive

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 before the U.S. financial markets open.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021.

Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022

Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer, will be participating at the 4th Annual Sachs Associates Neuroscience Innovation Forum taking place from Wednesday, April 28 to Friday, April 30, 2021.

Conventus-Flower Orthopedics, a medical device company focused on optimizing patient care by pioneering innovative solutions that address complex orthopedic challenges to streamline surgery, announced a partnership with Red One Medical, a private sector scout of medical innovation for the Department of Veterans Affairs and Department of Defense.

A notable number of DES approvals by Food and Drug Administration, China Food and Drug Administration, Japanese Ministry of Health, and other such regulatory authorities is driving growth in the global drug-eluting stents market.

Transparency Market Research delivers key insights on the global digital dose inhalers market.

According to a new TMR report, the benign prostatic hyperplasia treatment market is expected to grow at a robust 6% CAGR during 2019 to 2027.

DiaTrust™ received the U.S. Food and Drug Administration Emergency Use Authorization approval for their COVID-19 Point of Care antigen rapid test kit, DiaTrust™.

The global urinary tract infection treatment market is projected to amass a large amount of revenues in the coming years.